Key Breast Journal Articles - Endocrine

Disease Related Outcome with Long Term Follow-up: An Updated Analysis of the Intergroup Exemestane Study (IES)
JM Bliss, LS Kilbourn, RE Coleman, JF Forbes, AS Coates, SE Jones, J Jassem, T Delozier, J Anderson, RJ Paridaens & RC Coombes.
SABCS Abstracts 2009 [12]
Abstract

Survival and safety post study treatment completion: an updated analysis of the Intergroup Exemestane Study (IES) - submitted on behalf of the IES Investigators
R. Coombes, L Kilburn, S Beare, C Snowdon & J Bliss
ECCO Abstracts 2009. 7(2): 263
Abstract

BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
HT Mouridsen, A Giobbie-Hurder, L Mauriac, R Paridaens, M Colleoni, B Thuerlimann, JF Forbes, RD Gelber, A Wardley, I Smith, KN Price, A Coates, A Goldhirsch, BIG 1-98 Collaborative and the International Breast Cancer Study Group
SABCS Abstracts 2008
Abstract

Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada
S Verma, S Sehdev, & AA Joy
Curr Oncol. Dec 2007; 14 Suppl 1:S3-S10
Journal | Pubmed

Breast Cancer Adjuvant Endocrine Therapy
T Cigler & P Goss
Cancer J. May-Jun 2007; 13(3):148-55
Journal

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98
AS Coates, A Keshaviah, B Thürlimann, H Mouridsen, L Mauriac, JF Forbes, R Paridaens, M Castiglione-Gertsch, RD Gelber, M Colleoni, I Láng, L Del Mastro, I Smith, J Chirgwin, JM Nogaret, T Pienkowski, A Wardley, EH Jakobsen, KN Price, & A Goldhirsch
JCO. Feb 10 2007; 25(5):486-92
Article review by Dr S Verma | Journal | Pubmed

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial
F Boccardo, A Rubagotti, P Guglielmini, A Fini, G Paladini, M Mesiti, M Rinaldini, S Scali, M Porpiglia, C Benedetto, N Restuccia, F Buzzi, R Franchi, B Massidda, V Distante, D Amadori, P Sismondi & Other participants in the ITA trial
Ann Oncol. 17(suppl_7): vii10-14
Journal

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes
VG Vogel, JP Costantino, DL Wickerham, WM Cronin, RS Cecchini, JN Atkins, TB Bevers, L Fehrenbacher, ER Pajon Jr, JL Wade III, A Robidoux, RG Margolese, J James, SM Lippman, CD Runowicz, PA Ganz, SE Reis, W McCaskill-Stevens, LG Ford, VC Jordan, & N Wolmark; for the National Surgical Adjuvant Breast and Bowel Project (NSABP)
JAMA. Jun 21 2006; 295(23):2727-41
Journal | Pubmed

A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
The Breast International Group (BIG) 1-98 Collaborative Group
NEJM. Dec 29 2005; 353(26):2747-57
Journal | Pubmed

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, MJ Piccart, M Castiglione, D Tu, LE Shepherd, KI Pritchard, RB Livingston, NE Davidson, L Norton, EA Perez, JS Abrams, DA Cameron, MJ Palmer, JL Pater
J Natl Cancer Inst. 2005; 97(17):1262-71
Journal

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
R Jakesz, W Jonat, M Gnant, M Mittlboeck, R Greil, C Tausch, J Hilfrich, W Kwasny, C Menzel, H Samonigg, M Seifert, G Gademann & M Kaufmann
Lancet. Aug 6 2005; 366(9484):455-62
Journal

Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-year Survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet. May 14 2005; 365(9472):1687-1717
Journal

A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
RC Coombes, E Hall, LJ Gibson, R Paridaens, J Jassem, T Delozier, SE Jones, I Alvarez, G Bertelli, O Ortmann, AS Coates, E Bajetta, D Dodwell, RE Coleman, LJ Fallowfield, E Mickiewicz, J Andersen, PE Lønning, G Cocconi, A Stewart, N Stuart, CF Snowdon, M Carpentieri, G Massimini, & JM Bliss; the Intergroup Exemestane Study
NEJM. Mar 11 2004; 350(11):1081-92
Journal | Pubmed

HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped
L Holmberg & H Anderson, for the HABITS steering and data monitoring committees
Lancet. Feb 7 2004; 363(9407):453-5
Journal

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
PE Goss, JN Ingle, S Martino, NJ Robert, HB Muss, MJ Piccart, M Castiglione, D Tu, LE Shepherd, KI Pritchard, RB Livingston, NE Davidson, L Norton, EA Perez, JS Abrams, P Therasse, MJ Palmer, & JL Pater
NEJM. Nov 6 2003; 349(19):1793-1802
Journal | Pubmed

Anastrozole Alone or In Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-stage Breast Cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses
M Baum, A Buzdar, J Cuzick, J Forbes, J Houghton, A Howell, T Sahmoud, ATAC Trialists' Group
Cancer. Nov 1 2003; 98(9):1802-10
Pubmed

Advances in Endocrine Treatments for Postmenopausal Women with Metastatic and Early Breast Cancer
AU Buzdar
Oncologist. Aug 2003; 8(4):335-341
Journal

Anastrozole Alone or in Combination with Tamoxifen Versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: first results of the ATAC randomised trial
The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group
Lancet. June 22 2002; 359(9324):2131-9
Journal

Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
H Mouridsen, M Gershanovich, Y Sun, R Pérez-Carrión, C Boni, A Monnier, J Apffelstaedt, R Smith, HP Sleeboom, F Jänicke, A Pluzanska, M Dank, D Becquart, PP Bapsy, E Salminen, R Snyder, M Lassus, JA Verbeek, B Staffler, HA Chaudri-Ross, & M Dugan
JCO. May 15 2001; 19(10): 2596-606
Journal | Pubmed

Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial
B Fisher, J Dignam, J Bryant, & N Wolmark
J Natl Cancer Inst. May 2 2001; 93(9):684-90
Journal | Pubmed